Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2586 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 31.0 | 73 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 37.0 | 63 | |
RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 34.0 | 65 | |
RA1869 | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 35.0 | 66 | ||||
N2759 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 36.0 | 58 | |
N2759 | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 33.0 | 55 | ||||
RA1931 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 40.0 | 58 | |
RA1931 | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 35.0 | 55 | ||||
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 38.0 | 65 | |
N2586 | IL-1 alpha | 100 | ng/mL | 3 | IFN-a2 | 32.0 | 59 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 19.0 | 57 | |
RA1869 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 23.0 | 47 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 20.0 | 80 | |
N2759 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 20.0 | 57 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 19.0 | 75 | |
RA1931 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 22.0 | 71 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 20.0 | 71 | |
N2586 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 20.0 | 64 | |
RA1869 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 23.0 | 63 | |
RA1869 | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 20.5 | 66 | ||||
N2759 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 20.5 | 68 | |
N2759 | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 21.5 | 54 | ||||
RA1931 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 20.0 | 77 | |
RA1931 | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 21.5 | 52 | ||||
N2586 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | IFN-a2 | 23.0 | 64 |